Assembly Biosciences, Inc. (ASMB) Covered Calls
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics for serious viral diseases. The company focuses on two main areas: a chronic hepatitis B virus (HBV) program and a microbiome platform targeting inflammatory and metabolic diseases. Its pipeline includes potent HBV capsid assembly modulators designed to achieve a functional cure for HBV, alongside various small molecule candidates targeting the human microbiome.
You can sell covered calls on Assembly Biosciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ASMB (prices last updated Fri 4:16 PM ET):
| Assembly Biosciences, Inc. (ASMB) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 28.65 | -1.65 | 28.45 | 29.50 | 122K | - | 0.5 |
| Covered Calls For Assembly Biosciences, Inc. (ASMB) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Jun 18 | 30 | 1.55 | 27.95 | 5.5% | 57.4% | |
| Jul 17 | 30 | 2.00 | 27.50 | 7.3% | 41.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Assembly Biosciences, Inc. is a specialized biotechnology firm dedicated to advancing the treatment of chronic viral infections and diseases related to the microbiome. Headquartered in South San Francisco, California, the company leverages a deep understanding of viral lifecycles and microbial ecology to design targeted small-molecule therapies. Its primary strategic goal is to move beyond life-long suppressive treatments to provide curative solutions for millions of patients affected by chronic hepatitis B (HBV).
Core Business and Products
The company's lead research focus is its HBV program, which features a suite of next-generation capsid assembly modulators (CAMs). These candidates are designed to disrupt the HBV replication cycle at multiple points, with the ultimate objective of achieving a "functional cure" characterized by sustained viral clearance. Additionally, Assembly has developed a sophisticated microbiome platform involving live biotherapeutic products (LBPs). These oral, colon-targeted therapies aim to modulate the intestinal microbiota to treat diverse conditions, including ulcerative colitis and other immune-mediated disorders.
Competitive Landscape
The landscape for antiviral and microbiome research is highly competitive, with established pharmaceutical giants and nimble biotech firms vying for scientific breakthroughs. Assembly Biosciences competes based on its specialized chemical intellectual property and its focus on multi-pronged curative regimens. Key publicly traded, optionable competitors include:
- Gilead Sciences: A global leader in antiviral therapy that is a significant partner and competitor in the search for a functional HBV cure and advanced liver disease treatments.
- Vir Biotechnology: This immunology-focused company competes through the development of monoclonal antibodies and siRNA platforms aimed at chronic hepatitis B.
- Enanta Pharmaceuticals: A research-driven firm that competes in the development of small-molecule inhibitors for viral infections, including chronic HBV and respiratory viruses.
- Corbus Pharmaceuticals: A biotechnology peer that competes for institutional capital and scientific talent within the specialized inflammatory and fibrotic disease sectors.
- AbbVie Inc.: A major pharmaceutical company that competes in the broader immunology and gastrointestinal space where Assembly's microbiome candidates are positioned.
Strategic Outlook and Innovation
Assembly is increasingly focused on high-potency, next-generation HBV candidates that can be used in combination with other agents, such as nucleoside analogues and interferon. By targeting the viral capsid, the company aims to eliminate the reservoir of cccDNA that allows HBV to persist in the liver. Innovation efforts are also directed toward the "Gemini" program, which seeks to optimize the delivery of live microbial strains to specific regions of the gastrointestinal tract using proprietary encapsulation technology.
Strategically, the company has entered into high-profile collaborations to de-risk its pipeline and expand its commercial reach. The partnership with Gilead Sciences provides significant capital and technical resources to accelerate the development of its HBV portfolio. Moving forward, the company intends to maintain its leadership in viral assembly modulation while selectively advancing its microbiome assets through late-stage clinical trials. The long-term objective is to transform the standard of care for chronic viral diseases through precision chemistry and biological innovation.
| Top 10 Open Interest For Jun 18 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | IBIT covered calls | 1. | POET covered calls | |
| 2. | SLV covered calls | 7. | SPY covered calls | 2. | COIN covered calls | |
| 3. | KWEB covered calls | 8. | QQQ covered calls | 3. | UNH covered calls | |
| 4. | EWZ covered calls | 9. | XLF covered calls | 4. | MRVL covered calls | |
| 5. | EEM covered calls | 10. | FXI covered calls | 5. | NVTS covered calls | |
Want more examples? ASIX Covered Calls | ASML Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
